Questionnaire

1. By the time of T2DM diagnosis, the extent of β-cell function loss in most patients is:

2. Among risks associated with insulin therapy are:

3. At any level of severity, hypoglycaemia is associated with an increased risk of:

4. Basal insulin lowers FPG through the actions of inhibiting hepatic glucose production and decreasing adipocyte lipolysis, whereas GLP-1RAs reduce PPG excursions through the actions of stimulating insulin secretion, suppressing glucagon secretion, and slowing of gastric emptying.

5. When seeking to advance insulin therapy for the patient with suboptimal glycaemic control with current treatment, weight gain is a disadvantage of:

6. At Week 24 of the Soli-D study of participants with suboptimal T2DM control when using OADs, no difference between iGlarLixi and iDegAsp was observed for:

7. At Week 24 of the Soli-D study of participants with suboptimal T2DM control when using OADs, the total daily dose of insulin was lower with iDegAsp than with iGlarLixi.

8. At Week 24 of the Soli-SWITCH study of participants with T2DM switched from premixed insulin therapy to iGlarLixi found that treatment de-intensification was associated with:

9. Compared with a switch to iDegAsp in non-Asian adults with inadequate T2DM control when using basal insulin, a systematic review and meta analysis favoured iDegAsp for the outcomes of:

10. Compared with participants using twice-daily BIAsp 30 in the SoliMix study of suboptimal T2DM control when using basal insulin with one or two OADs, once-daily iGlarLixi treatment was associated with a statistically superior change from baseline to Week 26 in: